NCT07426419
An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)
Recruiting
PHASE1Ages 18–55InterventionalTreatmentAffinia Therapeutics
~22 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:AFTX-201
At a glance
Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Measured over Baseline through 12 months
Conditions
Where it's being run
3 sites across 3 statesFlorida1
Missouri1
Texas1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Baseline through 12 months
Safety and tolerability of AFTX-201 over 12 months.